Case Study: Takeda - Rixubis Launch

Executive Summary of the Project

More than 2700 Indians suffer from Hemophilia B. Most of the cases are still under-diagnosed and not registered. RIXUBIS - nonacog gamma, a recombinant human coagulation factor IX. Evolve with Rixubis and eliminate the threat from emerging pathogens as it is free from human and animal-derived products, thus, giving your patients the safety, they deserve. Rixubis is manufactured using a state-of-the-art process and purified using solvent detergent and 15 nm nano-filtration. Rixubis makes inclusive treatment a possibility as it is suitable for people across a wide age-group. Rixubis offers strong safety, powerful efficacy and comfort with convenience. Strong Safety - There have been zero reported incidences of inhibitor formation, thrombotic events and severe allergic reactions in all the age groups. Powerful efficacy - Rixubis resolves 89% bleeds with 1 to 2 infusions. With the aim of achieving 0 bleeds, Rixubis prevents 43% of the bleeds before they occur when followed prophylactic regime of twice a week infusion. Rixubis enables 100 percent factor 9 levels in peri and post-operative surgical settings. Rixubis delivers promising Incremental recovery and optimized dosage. What’s more! Upgrade to convenience with Rixubis It’s available in a wide range of potency, all in 5ml consistent volume for your convenience. Rixubis comes along with a needleless administration device, Baxject II, making quick and easy administration possible. Infusion with Rixubis can be done just within 30 seconds with administration rate of 10ml per minute The product has a 3 years shelf life even at room temperature up to 30 degrees Celsius. Twist the Fate of Hemophilia B patients with Rixubis. Embrace the Evolution, Embrace The New With Rixubis.